logo
Share SHARE
FONT-SIZE Plus   Neg

Celgene: Oral OTEZLA Shows Long-Term Benefits For Active Psoriatic Arthritis

Celgene International Sàrl, an unit of Celgene Corp. (CELG), reported results of additional analyses from the phase III trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 or PDE4. These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.

"People with psoriatic arthritis live with persistent symptoms of this painful disease," said Georg Schett, director of the Department of Internal Medicine III - Rheumatology and Immunology, University Hospital Erlangen, Germany. "These analyses of one-year data from the PALACE trials suggest that, based on the efficacy and safety data we've seen to-date, OTEZLA has the potential to help patients for the long-term management of manifestations of their psoriatic arthritis," he added.

The long-term (52-week) results from three trials showed that treatment with OTEZLA improved measures of psoriatic arthritis disease activity, including tender and swollen joints, compared with placebo at 16 weeks.

Long-term safety results from an analysis of pooled data from the PALACE 1, 2 and 3 trials identified no new safety findings for patients with psoriatic arthritis who were treated with OTEZLA for up to 52 weeks, compared with the previously reported 24-week safety results.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Fast food giant McDonald's on Wednesday announced its global growth plan, targeting sales growth of 3-5% beginning in 2019. The company also highlighted its vision for new restaurants relying on technology such as self-ordering kiosks, curbside pick ups and partnerships with delivery services. At... Canadian drug-maker Valeant Pharmaceuticals International, Inc. on Tuesday reported a loss for the fourth quarter that widened from last year on a double-digit decline in revenues. However, both revenue and adjusted earnings beat analysts' estimates. Valeant also said it plans to relaunch its sexual dysfunction drug Addyi in the U.S. Electronics retailer Best Buy Co., Inc. Wednesday issued guidance for first-quarter adjusted earnings and revenues, below market estimates. Comparable sales are expected to be weak. For fiscal 2018, the company projects higher revenues and operating income. In its fourth quarter, the company posted higher profit, above market view, while revenues missed estimates with lower comparable sales.
comments powered by Disqus
Follow RTT